Press releases Nektar in the news Items Per Page 10 25 50 News Category All Financial General Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Aug 28, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 25, 2026 Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Aug 13, 2026 Nektar Therapeutics Announces Second Quarter 2026 Financial Results Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets Jul 24, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Jun 26, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 03, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York May 07, 2026 Nektar Therapeutics Reports First Quarter 2026 Financial Results Contact IR Print Page RSS Email Alerts
Nektar in the news Items Per Page 10 25 50 News Category All Financial General Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Aug 28, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 25, 2026 Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Aug 13, 2026 Nektar Therapeutics Announces Second Quarter 2026 Financial Results Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets Jul 24, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Jun 26, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 03, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York May 07, 2026 Nektar Therapeutics Reports First Quarter 2026 Financial Results
Aug 25, 2026 Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
May 27, 2026 Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
